Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01293539 · ClinicalTrials.gov registry record · Phase 2
Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01293539 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 10 participants.
The verdict
NCT01293539, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to show that chemotherapy delivered directly through the artery supplying the eye (ophthalmic artery) to patients with retinoblastoma is a safe and effective treatment alternative to conventional systemic chemotherapy, external beam radiation, and surgical removal of the eye.
Interventions
- DRUG Melphalan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01293539
The ClinicalTrials.gov registry entry for NCT01293539 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Melphalan hydrochloride is the first listed.
NCT01293539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01293539 about?
NCT01293539 is a clinical study titled "Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma". The purpose of this study is to show that chemotherapy delivered directly through the artery supplying the eye (ophthalmic artery) to patients with retinoblastoma is a safe and effective treatment alternative to conventional systemic chemotherapy, external beam radiation, and surgical removal of the...
What is the current status of trial NCT01293539?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-03. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01293539?
The interventions under investigation include: Melphalan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01293539?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.